Treatment of malignant effusion

Close metadata

Malignant effusion complicates more than 15% of all cancers in delayed stages of progression. The most common causes of metastatic pleuritis are lung cancer, breast cancer, ovarian cancer, lymphoproliferative diseases or dissemination of gastrointestinal tumors. Malignant effusion is associated with negative prognosis for overall survival regardless of etiology of tumor, significantly complicates the course of the underlying disease, impairs life quality and complicates treatment. Despite various methods for pleural cavity obliteration in recurrent metastatic pleuritis, there is still no a uniform approach to choosing the optimal treatment strategy. We analyzed the main methods of conservative and surgical treatment of recurrent metastatic pleuritic regarding efficacy, risk of recurrence and reproducibility.

Keywords:

malignant effusion

pleurodesis

pleurectomy

pleural drainage

Authors:

Efteev L.A.

Clinical Oncological Hospital N. 1

ORCID: 0000-0002-9054-0742

Esakov Yu.S.

Moscow City Clinical Oncology Hospital No. 1

ORCID: 0000-0002-5933-924X

Blinova E.V.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0003-0050-0251

Bazylyuk A.V.

Clinical Oncological Hospital N. 1

ORCID: 0000-0003-0984-9783

Blinov K.D.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0009-0002-7195-2191

Received:

23.11.2023

Accepted:

26.02.2024

List of references:

Clive AO, Jones HE, Bhatnagar R, Preston NJ, Maskell N. Interventions for the management of malignant pleural effusions: a network meta-analysis. The Cochrane database of systematic reviews. 2016;2016(5):CD010529. https://doi.org/10.1002/14651858.CD010529.pub2
Gasol A, Bielsa S, Civit C, Light RW, Salud A. Clinical features and survival of lung cancer patients with pleural effusions. Respirology. 2015;20(4):654-659. https://doi.org/10.1111/resp.12496
American Thoracic Society. Management of malignant pleural effusions. American Journal of Respiratory and Critical Care Medicine. 2000;162(5):1987-2001. https://doi.org/10.1164/ajrccm.162.5.ats8-00
Feller-Kopman D, Light R. Pleural Disease. New England Journal of Medicine. 2018;378(8):740-751. https://doi.org/10.1056/nejmra1403503
Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65(suppl 2):32-40. https://doi.org/10.1136/thx.2010.136994
Ost DE, Niu J, Zhao H, Grosu HB, Giordano SH. Quality gaps and comparative effectiveness of management strategies for recurrent malignant pleural effusions. Chest. 2018;153(2):438-452. https://doi.org/10.1016/j.chest.2017.08.026
Stathopoulos GT. Translational advances in pleural malignancies. Respirology. 2011;16(1):53-63. https://doi.org/10.1111/j.1440-1843.2010.01890.x
Stathopoulos GT, Kalomenidis I. Malignant pleural effusion: tumor-host interactions unleashed. American Journal of Respiratory and Critical Care Medicine. 2012;186(6):487-492. https://doi.org/10.1164/rccm.201203-0465PP
Jovanovic D. Etiopathogenesis of malignant pleural effusion. AME Medical Journal. 2021;6:28. https://doi.org/10.21037/amj-2019-mpe-05
Psallidas I, Kalomenidis I, Porcel JM, Robinson BW, Stathopoulos GT. Malignant pleural effusion: From bench to bedside. European Respiratory Review. 2016;25:189-198. https://doi.org/10.1183/16000617.0019-2016
Agalioti T, Giannou AD, Krontira AC, Kanellakis NI, Kati D, Vreka M, Pepe M, Spella M, Lilis I, Zazara DE. Mutant KRAS promotes malignant pleural effusion formation. Nature Communications. 2017;8:15205. https://doi.org/10.1038/ncomms15205
Stathopoulos GT, Kalomenidis I. Malignant pleural effusion: Tumor-host interactions unleashed. American Journal of Respiratory and Critical Care Medicine. 2012;186:487-492. https://doi.org/10.1164/rccm.201203-0465PP
Desai NR, Lee HJ. Diagnosis and management of malignant pleural effusions: State of the art in 2017. Journal of Thoracic Disease. 2017;9:S1111-S1122. https://doi.org/10.21037/jtd.2017.07.79
Mishra EK, Muruganandan S, Clark A, Bhatnagar R, Maskell N, Lee YCG, Rahman NM. Breathlessness Predicts Survival in Patients With Malignant Pleural Effusions: Meta-analysis of Individual Patient Data From Five Randomized Controlled Trials. Chest. 2021;160:351-357. https://doi.org/10.1016/j.chest.2021.02.052
Schnell D, Mayaux J, Lambert J, Roux A, Moreau AS, Zafrani L, Canet E, Lemiale V, Darmon M, Azoulay É. Clinical assessment for identifying causes of acute respiratory failure in cancer patients. European Respiratory Journal. 2012;42:435-443. https://doi.org/10.1183/09031936.00122512
Grimberg A, Shigueoka DC, Atallah AN, Ajzen SA, Iared W. Diagnostic accuracy of sonography for pleural effusion: Systematic review. Sao Paulo Medical Journal. 2010;128:90-95. https://doi.org/10.1590/S1516-31802010000200009
Porcel JM, Pardina M, Bielsa S, González A, Light RW. Derivation and Validation of a CT Scan Scoring System for Discriminating Malignant From Benign Pleural Effusions. Chest. 2015;147:513-519. https://doi.org/10.1378/chest.14-0013
Fjaellegaard K, Petersen JK, Reuter S, Fischer BM, Gerke O, Porcel JM, Clementsen PF, Laursen CB, Bhatnagar R, Bodtger U. Positron emission tomography-computed tomography (PET-CT) in suspected malignant pleural effusion. An updated systematic review and meta-analysis. Lung Cancer. 2021;162:106-118. https://doi.org/10.1016/j.lungcan.2021.10.018
Feller-Kopman DJ, Reddy CB, DeCamp MM, Diekemper RL, Gould MK, Henry T, Iyer NP, Lee YCG, Lewis SZ, Maskell NA. Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine. 2018;198:839-849. https://doi.org/10.1164/rccm.201807-1415ST
Kassirian S, Hinton SN, Cuninghame S, Chaudhary R, Iansavitchene A, Amjadi K, Dhaliwal I, Zeman-Pocrnich C, Mitchell M. Diagnostic sensitivity of pleural fluid cytology in malignant pleural effusions: Systematic review and meta-analysis. Thorax. 2023;78:32-40. https://doi.org/10.1136/thoraxjnl-2021-217959
Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65(2):32-40. https://doi.org/10.1136/thx.2010.136994
Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65(2):32-40. https://doi.org/10.1136/thx.2010.136994
Filonenko EV, Pikin OV, Trahtenberg AH, Sokolov VV, Vursol DA, Krylova GP. Intrapleural prolonged photodynamic therapy in patients with malignant effusion. Biomedical Photonics. 2015;4(1):78. (In Russ.).
Levchenko EV, Mamontov OYu, Senchik KYu, Barchuk AS, Gelfond ML. Using a multimodal approach in the treatment of patients with malignant effusion. Voprosy onkologii. 2015;61(3):401-406. (In Russ.).
Zhestkov KG, Yaduta RT. Thoracoscopic pleurectomy decortication with metastatic pleurisy: aspects of surgical techniques. Povolzhskij onkologicheskij vestnik. 2016;2:43-47. (In Russ.).
Perevodchikova NI, Alekseeva TR. Metestatic pleurisy: diagnosis and choice of therapeutic tactics. Mezhdunarodnyj medicinskij zhurnal. 2003;4:88-93. (In Russ.).
Scarci M, Caruana E, Bertolaccini L, Bedetti B, Brunelli A, Varela G, Papagiannopoulos K, Kuzdzal J, Massard G, Ruffini E, Falcoz PE, Opitz I, Batirel H, Toker A, Rocco G. ESTS Malignant Pleural Effusion Working Group. Current practices in the management of malignant pleural effusions: a survey among members of the European Society of Thoracic Surgeons. Interactive CardioVascular and Thoracic Surgery. 2017;24(3):414-417. https://doi.org/10.1093/icvts/ivw373
Wong-Arteta J, Rey M, Aragón L, Gil-Rodríguez E, Bujanda L. The utility of flow cytometry in the diagnostic work up of malignant effusions due to nonhematopoietic neoplasms. Cytometry Part B: Clinical Cytometry. 2020;98:504-515. https://doi.org/10.1002/cyto.b.21886
Beltsios ET, Mavrovounis G, Adamou A, Panagiotopoulos N. Talc pleurodesis in malignant pleural effusion: A systematic review and meta-analysis. General Thoracic and Cardiovascular Surgery. 2020;69:832-842. https://doi.org/10.1007/s11748-020-01549-2
Bhatnagar R, Piotrowska HEG, Laskawiec-Szkonter M, Kahan BC, Luengo-Fernandez R, Pepperell JCT, Evison MD, Holme J, Al-Aloul M, Psallidas I. Effect of Thoracoscopic Talc Poudrage vs Talc Slurry via Chest Tube on Pleurodesis Failure Rate among Patients with Malignant Pleural Effusions: A Randomized Clinical Trial. JAMA. 2020;323:60-69. https://doi.org/10.1001/jama.2019.19997
Olivares-Torres CA, Laniado-Laborín R, Chávez-García C, León-Gastelum C, Reyes-Escamilla A, Light RW. Iodopovidone Pleurodesis for Recurrent Pleural Effusions. Chest. 2002;122:581-583. https://doi.org/10.1378/chest.122.2.581
Mohsen TA, Zeid AAA, Meshref M, Tawfeek N, Redmond K, Ananiadou OG, Haj-Yahia S. Local iodine pleurodesis versus thoracoscopic talc insufflation in recurrent malignant pleural effusion: A prospective randomized control trial. European Journal of Cardio-Thoracic Surgery. 2010;40:282-286. https://doi.org/10.1016/j.ejcts.2010.09.005
Davies HE, Mishra EK, Kahan BC, Wrightson J, Stanton AE, Guhan A, Davies CWH, Grayez J, Harrison R, Prasad A. Effect of an Indwelling Pleural Catheter vs Chest Tube and Talc Pleurodesis for Relieving Dyspnea in Patients With Malignant Pleural Effusion: The TIME2 Randomized Controlled Trial. JAMA. 2012;307:2383-2389. https://doi.org/10.1001/jama.2012.5535
Iyer NP, Reddy CB, Wahidi MM, Lewis SZ, Diekemper RL, Feller-Kopman D, Gould MK, Balekian AA. Indwelling Pleural Catheter versus Pleurodesis for Malignant Pleural Effusions. A Systematic Review and Meta-Analysis. Annals of the American Thoracic Society. 2019;16:124-131. https://doi.org/10.1513/AnnalsATS.201807-495OC
Mc Miller CRJ, Chrissian AA, Lee YCGM, Rahman NM, Wahidi MMM, Tremblay AM, Hsia DW, Almeida FAM, Shojaee SM, Mudambi L. AABIP Evidence-informed Guidelines and Expert Panel Report for the Management of Indwelling Pleural Catheters. Journal of Bronchology & Interventional Pulmonology. 2020;27:229-245. https://doi.org/10.1097/LBR.0000000000000707
Wahidi MM, Reddy C, Yarmus L, Feller-Kopman D, Musani A, Shepherd RW, Lee H, Bechara R, Lamb C, Shofer S. Randomized Trial of Pleural Fluid Drainage Frequency in Patients with Malignant Pleural Effusions. The ASAP Trial. American Journal of Respiratory and Critical Care Medicine. 2017;195:1050-1057. https://doi.org/10.1164/rccm.201607-1404OC
Muruganandan S, Azzopardi M, Fitzgerald DB, Shrestha R, Kwan BCH, Lam DCL, De Chaneet CC, Ali MRSR, Yap E, Tobin CL. Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): An open-label randomisedtrial. The Lancet Respiratory Medicine. 2018;6:671-680. https://doi.org/10.1016/S2213-2600(18)30288-1
Sundaralingam A, Bedawi EO, Harriss EK, Munavvar M, Rahman NM. The Frequency, Risk Factors, and Management of Complications From Pleural Procedures. Chest. 2021;161:1407-1425. https://doi.org/10.1016/j.chest.2021.11.031
Bhatnagar R, Keenan EK, Morley AJ. Outpatient talc administration by indwelling pleural catheter for malignant effusion. The New England Journal of Medicine. 2018;378(14):1313-1322. https://doi.org/10.1056/nejmoa1716883
Rintoul RC, Ritchie AJ, Edwards JG. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. The Lancet. 2014;384(9948):1118-1127. https://doi.org/10.1016/s0140-6736(14)60418-9

Close metadata